Oral Medication Shows Positive Results for Achondroplasia in Children

BridgeBio Pharma's Phase 3 PROPEL 3 study of oral infigratinib for children with achondroplasia has yielded positive results, published in The New England Journal of Medicine. The trial demonstrated significant improvements in height velocity, height Z-score, and body proportionality. The company plans to submit a New Drug Application to the FDA in the third quarter of 2026, potentially offering a new treatment option.